Tumour Antigen Choice - Key Publications



Publications are listed according to year, with the most recent first. Within each year, publications are listed in alphabetical order, based on the first author’s surname. Click on “Publication link” to access the publication on PubMed. Use the search box above to find particular publications based on author or terms in the title.


  • Robo4 vaccines induce antibodies that retard tumor growth

    Zhuang X, Ahmed F, Zhang Y, Ferguson HJ, Steele JC, Steven NM, Nagy Z, Heath VL, Toellner K.-M. and Bicknell R.

    Angiogenesis 2015. 18: 83-95.

  • Vaccination against tumour blood vessels in colorectal cancer

    Ferguson HJ, Wragg J, Ismail T, Bicknell R.

    Eur J Surg Oncol 40(2):133-6 (2014)

  • EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era

    Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, Shaw BE, Byrne JL, Brookes C, Craddock CF, Chaganti S.

    Bone Marrow Transplant. 2014 Feb;49(2):280-6.

  • Lenalidomide and second malignancies in myeloma patients

    Pratt G.

    Lancet Oncol. 2014 Mar;15(3):253-4.

  • Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden

    Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, Landgren O.

    Blood. 2014 Jan 16;123(3):338-45.

  • Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

    Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A, Kottaridis P, Grimwade D, Khwaja A, Stauss H, Morris EC.

    Br J Haematol. 2014 Feb;164(3):366-75.